

Sarah A M Cuddy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3412600/publications.pdf>

Version: 2024-02-01

29
papers

711
citations

1040056

9
h-index

642732

23
g-index

30
all docs

30
docs citations

30
times ranked

1093
citing authors

#	ARTICLE	IF	CITATIONS
1	Prognostic Value of Cardiac Magnetic Resonance Tissue Characterization in Risk Stratifying Patients With Suspected Myocarditis. <i>Journal of the American College of Cardiology</i> , 2017, 70, 1964-1976.	2.8	303
2	How to Image Cardiac Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1368-1383.	5.3	156
3	Absolute Quantitation of Cardiac ^{99m} Tc-Pyrophosphate Using Cadmium-Zinc-Telluride-Based SPECT/CT. <i>Journal of Nuclear Medicine</i> , 2021, 62, 716-722.	5.0	51
4	Improved Quantification of Cardiac Amyloid Burden in Systemic Light Chain Amyloidosis. <i>JACC: Cardiovascular Imaging</i> , 2020, 13, 1325-1336.	5.3	41
5	Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis. <i>European Heart Journal Cardiovascular Imaging</i> , 2022, 23, 1029-1039.	1.2	33
6	Amyloidosis as a Systemic Disease in Context. <i>Canadian Journal of Cardiology</i> , 2020, 36, 396-407.	1.7	28
7	Left atrial structure and function of the amyloidogenic V122I transthyretin variant in elderly African Americans. <i>European Journal of Heart Failure</i> , 2021, 23, 1290-1295.	7.1	19
8	Incidental Coronary Artery Calcification in Cancer Imaging. <i>JACC: CardioOncology</i> , 2019, 1, 135-137.	4.0	14
9	Quantitative [18F]florbetapir PET/CT may identify lung involvement in patients with systemic AL amyloidosis. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 1998-2009.	6.4	14
10	Appropriateness of inpatient stress testing: Implications for development of clinical decision support mechanisms and future criteria. <i>Journal of Nuclear Cardiology</i> , 2021, 28, 1988-1997.	2.1	9
11	Effect of Tafamidis on Serum Transthyretin Levels in Non-Trial Patients With Transthyretin Amyloid Cardiomyopathy. <i>JACC: CardioOncology</i> , 2021, 3, 580-586.	4.0	9
12	Multimodality Imaging in the Evaluation and Management of Cardiac Amyloidosis. <i>Seminars in Nuclear Medicine</i> , 2020, 50, 295-310.	4.6	6
13	Myocardial Composition in Light-Chain Cardiac Amyloidosis More Than 1 Year After Successful Therapy. <i>JACC: Cardiovascular Imaging</i> , 2022, 15, 594-603.	5.3	6
14	Complexities and Pitfalls in Cardiac Amyloidosis. <i>Circulation</i> , 2020, 142, 409-415.	1.6	5
15	Initial Monthly Cost of Tafamidis—the Real Price for Patients. <i>JAMA Cardiology</i> , 2020, 5, 847.	6.1	4
16	Imaging of cardiac amyloidosis: Will this become a unique application for dual-isotope imaging?. <i>Journal of Nuclear Cardiology</i> , 2020, 27, 38-40.	2.1	3
17	Editorial: 18F-Fluoride PET/MR in cardiac amyloid; simple addition versus synergy?. <i>Journal of Nuclear Cardiology</i> , 2022, 29, 750-752.	2.1	2
18	Multimodality Imaging in Cardiac Amyloidosis. <i>Current Cardiology Reports</i> , 2021, 23, 134.	2.9	2

#	ARTICLE	IF	CITATIONS
19	A novel substitution of proline (P32L) destabilises β 2-microglobulin inducing hereditary systemic amyloidosis. <i>Amyloid: the International Journal of Experimental and Clinical Investigation: the Official Journal of the International Society of Amyloidosis</i> , 2022, , 1-8.	3.0	2
20	Use of Multimodality Imaging in Diagnosing Invasive Fungal Diseases of the Heart. <i>Circulation: Cardiovascular Imaging</i> , 2017, 10, .	2.6	1
21	Rhabdomyolysis in the Setting of Concomitant Use of Tafamidis, Atorvastatin, and Amiodarone. <i>JACC: Case Reports</i> , 2020, 2, 2372-2375.	0.6	1
22	Deletion of entire LMNA gene as a cause of cardiomyopathy. <i>HeartRhythm Case Reports</i> , 2020, 6, 395-397.	0.4	1
23	Young Male With Stab Wound. <i>Annals of Emergency Medicine</i> , 2017, 69, 171-201.	0.6	0
24	What is this image? 2018: image 6 result. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 720-723.	2.1	0
25	CARDIAC MAGNETIC RESONANCE IMAGING FOR DIAGNOSIS OF LOEFFLER'S ENDOCARDITIS. <i>Journal of the American College of Cardiology</i> , 2018, 71, A2269.	2.8	0
26	Molecular Imaging of Cardiac Amyloidosis. <i>Current Cardiovascular Imaging Reports</i> , 2018, 11, 1.	0.6	0
27	CMR AND ECHOCARDIOGRAPHIC ASSESSMENT OF LEFT VENTRICULAR STRAIN IN TRANSTHYRETIN CARDIAC AMYLOIDOSIS. <i>Journal of the American College of Cardiology</i> , 2019, 73, 1559.	2.8	0
28	Phenotyping of Cardiac Amyloidosis. <i>Circulation: Cardiovascular Imaging</i> , 2020, 13, e010785.	2.6	0
29	Letter by Falk et al Regarding Article, "False-Positive ^{99m} Tc-Technetium-Pyrophosphate Scintigraphy in Two Patients With Hypertrophic Cardiomyopathy". <i>Circulation: Heart Failure</i> , 2022, 15, 101161CIRCHEARTFAILURE121008636.	3.9	0